Breaking News Instant updates and real-time market news.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

, REGN

Regeneron

$373.47

-12.58 (-3.26%)

07:06
10/13/16
10/13
07:06
10/13/16
07:06

Ocular Therapeutix outlines strategy for sustained release intravitreal depots

Ocular Therapeutix (OCUL) provided an update on the company's development strategy for its sustained release intravitreal depot technology for the treatment of serious retinal diseases. The company is currently developing proprietary sustained-release hydrogel-based drug delivery depots for intravitreal injection that can be formulated with both small and large molecule pharmaceuticals, such as tyrosine kinase inhibitors and protein-based anti-vascular endothelial growth factors respectively, with the goal of delivering sustained and therapeutic levels of drugs to targeted ocular tissues. The goal of the company's intravitreal depot dual development program is to reduce the frequency of injections that are currently the standard of care for the treatment of wet AMD, DME and other retinal diseases. Accordingly, Ocular Therapeutix also announced today that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (REGN) for the development of a sustained release formulation of Regeneron's VEGF trap, aflibercept, for the treatment of wet age-related macular degeneration and other serious retinal diseases. Regeneron's aflibercept is currently approved by the U.S. FDA for certain indications under the brand name EYLEA. Per the agreement, Ocular Therapeutix retains all rights to develop its sustained-release hydrogel-based drug delivery platform with all other non-VEGF targeting compounds as well as with small molecule pharmaceuticals, including TKIs, for other retinal diseases.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

REGN

Regeneron

$373.47

-12.58 (-3.26%)

  • 30

    Oct

  • 04

    Nov

  • 29

    Nov

  • 29

    Mar

OCUL Ocular Therapeutix
$6.31

-0.2 (-3.07%)

06/06/16
COWN
06/06/16
NO CHANGE
Target $60
COWN
Outperform
Ocular OTX-DP data miss 'meaningless' to Outperform thesis, says Cowen
Cowen said that while any clinical trial failure of any kind is always a disappointment, the OTX-DP miss in allergic conjunctivitis reported by Ocular Therapeutix is "meaningless" to the firm's thesis, which is predicated "nearly entirely" on the OTX-TP opportunity for the treatment of glaucoma. The firm keeps an Outperform rating and $60 price target on Ocular shares.
06/07/16
MSCO
06/07/16
NO CHANGE
Target $16
MSCO
Overweight
Ocular Therapeutix weakness an overreaction, says Morgan Stanley
Morgan Stanley analyst Andrew Berens said the initial investor reaction to the failure of the second Phase III trial for Dextenza in allergic conjunctivitis appears extreme. Berens said he assigned little direct value for the allergy opportunity and does not see a read through to the post-op indication. The analyst said the focus remains on Dextenza's July 24 PDUFA in post surgical pain and maintains his Overweight rating on Ocular and $16 price target.
07/26/16
RBCM
07/26/16
NO CHANGE
RBCM
Ocular Therapeutix risk/reward still positive, says RBC Capital
After the FDA issued a complete response letter for Ocular's Dextenza, RBC Capital analyst Adnan Butt notes that the agency did not ask for more safety or efficacy data about the drug. According to the analyst, the company has already issued a response to the letter, and the FDA's reply could come in one to three months. Butt thinks that the stock could still advance if Dextenza and a number of its other drugs are approved. The analyst trimmed the price target on the shares to $38 from $40 but keeps an Outperform rating on the stock.
08/11/16
JMPS
08/11/16
INITIATION
Target $21
JMPS
Outperform
Ocular Therapeutix initiated with an Outperform at JMP Securities
Target $21.
REGN Regeneron
$373.47

-12.58 (-3.26%)

09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.

TODAY'S FREE FLY STORIES

MS

Morgan Stanley

$55.35

0.75 (1.37%)

, BK

BNY Mellon

$57.89

0.35 (0.61%)

20:25
01/17/18
01/17
20:25
01/17/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MS

Morgan Stanley

$55.35

0.75 (1.37%)

BK

BNY Mellon

$57.89

0.35 (0.61%)

BBT

BB&T

$53.28

0.2 (0.38%)

PPG

PPG

$114.50

-2.14 (-1.83%)

MTB

M&T Bank

$179.21

1.43 (0.80%)

KEY

KeyCorp

$21.26

-0.06 (-0.28%)

JBHT

J.B. Hunt

$120.65

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 08

    Mar

  • 10

    May

ARNA

Arena Pharmaceuticals

$34.36

0.48 (1.42%)

20:24
01/17/18
01/17
20:24
01/17/18
20:24
Initiation
Arena Pharmaceuticals initiated  »

Arena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROSE

Rosehill Resources

$7.96

0.01 (0.13%)

20:12
01/17/18
01/17
20:12
01/17/18
20:12
Initiation
Rosehill Resources initiated  »

Rosehill Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

20:10
01/17/18
01/17
20:10
01/17/18
20:10
Initiation
ConocoPhillips initiated  »

ConocoPhillips initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

HES

Hess Corp.

$54.02

0.48 (0.90%)

20:10
01/17/18
01/17
20:10
01/17/18
20:10
Initiation
Hess Corp. initiated  »

Hess Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

OXY

Occidental Petroleum

$75.86

0.59 (0.78%)

20:10
01/17/18
01/17
20:10
01/17/18
20:10
Initiation
Occidental Petroleum initiated  »

Occidental Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

JUNO

Juno Therapeutics

$69.25

23.65 (51.86%)

19:53
01/17/18
01/17
19:53
01/17/18
19:53
Downgrade
Juno Therapeutics rating change  »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WP

Worldpay

$77.89

-0.37 (-0.47%)

19:52
01/17/18
01/17
19:52
01/17/18
19:52
Upgrade
Worldpay rating change  »

Worldpay upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRAC

Keane Group

$18.51

0.63 (3.52%)

19:52
01/17/18
01/17
19:52
01/17/18
19:52
Syndicate
Keane Group 13.3M share Secondary priced at $18.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

BOOT

Boot Barn

$18.00

-1.1 (-5.76%)

19:50
01/17/18
01/17
19:50
01/17/18
19:50
Syndicate
Boot Barn 6M share Secondary priced at $17.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

PGH

Pengrowth Energy

$0.82

-0.0076 (-0.92%)

19:27
01/17/18
01/17
19:27
01/17/18
19:27
Hot Stocks
Pengrowth Energy announces $65M 2018 capital budget »

Pengrowth Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$44.39

1.25 (2.90%)

19:24
01/17/18
01/17
19:24
01/17/18
19:24
Hot Stocks
Intel says issued firmware updates for 90% of CPUs in past vie years »

Intel said it has made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

OBE

Obsidian Energy

$1.21

-0.03 (-2.42%)

19:21
01/17/18
01/17
19:21
01/17/18
19:21
Hot Stocks
Obsidian Energy says willing to work with FrontFour on board views »

Obsidian Energy confirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOSBF

Toshiba, also use TOSYY

, TOSYY

Toshiba, also use TOSBF

$16.95

-0.01 (-0.06%)

19:11
01/17/18
01/17
19:11
01/17/18
19:11
Periodicals
Toshiba's Westinghouse to forgo bankruptcy, Reuters reports »

Westinghouse Electric…

TOSBF

Toshiba, also use TOSYY

TOSYY

Toshiba, also use TOSBF

$16.95

-0.01 (-0.06%)

BAM

Brookfield

$43.10

0.42 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$70.20

0.22 (0.31%)

, RDS.B

Royal Dutch Shell

$72.34

0.35 (0.49%)

19:02
01/17/18
01/17
19:02
01/17/18
19:02
Periodicals
Shell, BP each agree to purchase Libyan oil, Bloomberg reports »

Royal Dutch Shell (RDS.A)…

RDS.A

Royal Dutch Shell

$70.20

0.22 (0.31%)

RDS.B

Royal Dutch Shell

$72.34

0.35 (0.49%)

BP

BP

$42.88

0.42 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AAPL

Apple

$179.10

2.91 (1.65%)

18:31
01/17/18
01/17
18:31
01/17/18
18:31
Hot Stocks
Trump says Apple investments 'huge win for American workers' »

President Donald Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

MPVD

Mountain Province Diamonds

$2.83

0.075 (2.73%)

18:22
01/17/18
01/17
18:22
01/17/18
18:22
Hot Stocks
Mountain Province Diamonds provides update on Gahcho Kue Mine exploration »

Mountain Province…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAC

Walter Investment

$0.76

0.0347 (4.81%)

18:17
01/17/18
01/17
18:17
01/17/18
18:17
Hot Stocks
Walter Investment prepackaged Chapter 11 plan approved by court »

Walter Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

$140.72

2.75 (1.99%)

, KBSTY

Kobe Steel

18:10
01/17/18
01/17
18:10
01/17/18
18:10
Periodicals
Toyota not affected by Kobe Steel false data scandal, Nikkei reports »

Toyota (TM) said there…

TM

Toyota

$140.72

2.75 (1.99%)

KBSTY

Kobe Steel

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBOE

Cboe Global Markets

$131.52

0.73 (0.56%)

, BTC

Bitcoin

17:47
01/17/18
01/17
17:47
01/17/18
17:47
Hot Stocks
Cboe conducts first settlement of Cboe bitcoin futures »

Cboe Global Markets…

CBOE

Cboe Global Markets

$131.52

0.73 (0.56%)

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

GWRE

Guidewire

$75.64

0.19 (0.25%)

17:46
01/17/18
01/17
17:46
01/17/18
17:46
Hot Stocks
Guidewire director sells 6,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.10

2.91 (1.65%)

17:40
01/17/18
01/17
17:40
01/17/18
17:40
Recommendations
Apple analyst commentary at Piper Jaffray »

Apple cash repatriation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

OBE

Obsidian Energy

$1.21

-0.03 (-2.42%)

17:36
01/17/18
01/17
17:36
01/17/18
17:36
Hot Stocks
Breaking Hot Stocks news story on Obsidian Energy »

FrontFour reports 5.7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SN

Sanchez Energy

$5.81

0.16 (2.83%)

17:33
01/17/18
01/17
17:33
01/17/18
17:33
Hot Stocks
Breaking Hot Stocks news story on Sanchez Energy »

Sanchez Energy sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

SN

Sanchez Energy

$5.81

0.16 (2.83%)

17:32
01/17/18
01/17
17:32
01/17/18
17:32
Hot Stocks
Sanchez Energy sees FY18 capital budget of $420M-$470M »

Sanchez Energy 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.